Acumen Pharmaceuticals In... (ABOS)
0.99
-0.09 (-8.33%)
At close: Apr 03, 2025, 1:56 PM
Company Description
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for the treatment of Alzheimer's disease.
The company focuses on advancing a targeted immunotherapy drug candidate ACU193, a humanized monoclonal antibody that is in Phase I clinical-stage to target soluble amyloid-beta oligomers.
Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Charlottesville, Virginia.
Acumen Pharmaceuticals Inc.

Country | United States |
IPO Date | Jul 1, 2021 |
Industry | Biotechnology |
Sector | Healthcare |
Employees | 61 |
CEO | Daniel J. O'Connell M.B.A. |
Contact Details
Address: 427 Park Street Charlottesville, Virginia United States | |
Website | https://acumenpharm.com |
Stock Details
Ticker Symbol | ABOS |
Exchange | NASDAQ |
Fiscal Year | January - December |
Reporting Currency | USD |
CIK Code | 0001576885 |
CUSIP Number | 00509G209 |
ISIN Number | US00509G2093 |
Employer ID | 36-4108129 |
SIC Code | 2836 |
Key Executives
Name | Position |
---|---|
Daniel J. O'Connell M.B.A. | Chief Executive Officer & Director |
Derek M. Meisner Esq., J.D. | Chief Legal Officer & Corporate Secretary |
Matt Zuga | Chief Financial Officer & Chief Business Officer |
Russell Barton M.S. | Chief Operating Officer |
Alex Braun M.B.A. | Vice President & Head of Investor Relations |
Dr. Caleb E. Finch Ph.D. | Co-Founder |
Dr. Grant A. Krafft Ph.D. | Co-Founder |
Dr. James Doherty Ph.D. | President & Chief Development Officer |
Dr. William L. Klein Ph.D. | Co-Founder |
Kelly Carranza | Vice President, Finance & Accounting and Corporate Controller |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Mar 31, 2025 | SCHEDULE 13D/A | [Amend] Filing |
Mar 27, 2025 | S-8 | Filing |
Mar 27, 2025 | 10-K | Annual Report |
Mar 27, 2025 | 8-K | Current Report |
Jan 23, 2025 | 4 | Filing |
Jan 23, 2025 | 4 | Filing |
Jan 23, 2025 | 4 | Filing |
Jan 23, 2025 | 4 | Filing |
Jan 23, 2025 | 4 | Filing |
Jan 07, 2025 | 4 | Filing |